Responsiveness to pulmonary rehabilitation in people with COPD is associated with

1

2 changes in microbiota 3 Sara Melo-Dias^{1,2,3}, Msc, Miguel Cabral^{1,3}, Bsc, Andreia Furtado^{1,3}, Msc, Sara Souto-Miranda^{2,4}, Msc, Maria Aurora Mendes^{3,5}, MD, João Cravo⁵, MD, Catarina R. Almeida^{1,3}, PhD, Alda Marques^{2,3}, PhD‡ and Ana Sousa^{1,3}, PhD‡ 4 5 Affiliations: 6 7 ¹Department of Medical Sciences, University of Aveiro, Aveiro, Portugal; ²Lab3R – Respiratory Research and Rehabilitation Laboratory, School of Health Sciences (ESSUA), University of Aveiro, Aveiro, Portugal; ³Institute of Biomedicine (iBiMED), 8 9 University of Aveiro, Aveiro, Portugal; ⁴Department of Respiratory Medicine, Maastricht University Medical Centre, NUTRIM School of Nutrition and Translational Research in Metabolism, Faculty of Health, Medicine and Life Sciences, Maastricht 10 University, Maastricht, The Netherlands.; 5Department of Pulmonology of the Hospital Center of Baixo Vouga 11 ‡These authors contributed equally to this study. 12 Correspondence: Ana Sousa, Department of Medical Sciences, Institute of Biomedicine, University of Aveiro, 13 3810-193 Aveiro, Portugal (amsousa@ua.pt) **Abstract** 14 Rationale: Pulmonary Rehabilitation (PR) is one of the most cost-effective therapies for 15 chronic obstructive pulmonary disease (COPD) management. There are, however, people who 16 do not respond to PR and reasons for non-response are mostly unknown. PR is likely to change 17 the airway microbiota and this could play a role in its responsiveness. 18 19 Objectives: In this study we have explored the association between PR effectiveness and 20 specific alterations in oral microbiota and inflammation. 21 Methods: A prospective longitudinal study was conducted. Data on exercise capacity, 22 dyspnoea, impact of disease and 418 saliva samples were collected from 76 patients, half of 23 whom participated in a 12-weeks PR programme. Responders and non-responders to PR 24 (dyspnoea, exercise-capacity and impact of disease) were defined based on minimal clinically important differences. 25 26 Measurements and Main Results: Changes in microbiota, including Prevotella 27 rNeTerThiogenificerante retreptoetobetos we reco beteinded epocryiPRarPrepoble/Acpereurously-foicate acide

depleted in severe COPD, increased during the first month of PR in responders. This increase was negatively correlated with *Streptoccus* and *Lautropia*, known to be enriched in severe cases of COPD. Simultaneously, an anti-inflammatory commensal of the respiratory tract, *Rothia*, correlated strongly and negatively with several pro-inflammatory markers, whose levels were generally boosted by PR.

Conversely, in non-responders, the observed decline in *Prevotella* correlated negatively with *Streptococcus* and *Lautropia* whose fluctuations co-occurred with several pro-inflammatory markers.

Conclusions: PR is associated with changes in oral microbiota. Consistent patterns of bacteria/pro-inflammatory markers among responders and non-responders were unraveled, which may contribute to explain the success of PR.

Key words: oral microbiota; inflammation; COPD; pulmonary rehabilitation; responsiveness

Introduction

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

Chronic obstructive pulmonary disease (COPD) is heterogenous and complex and therefore, difficult to treat and manage. Pulmonary rehabilitation (PR) is a grade A non-pharmacological therapy and one of the most cost-effective approaches for the management of COPD (1). Compared to pharmacological treatment, PR is three to five times more effective in improving exercise capacity, dyspnoea, and quality of life (2). Response to PR is however multidimensional and heterogeneous, which means that for the same outcome patients are not equally responsive (3). Reasons behind non-response are mostly unknown (3, 4). An association between the airway microbiota, including the oral microbiota (5), and disease severity has been extensively established in people with COPD (6-8). However, the impact of PR on the airway microbiota has not yet been investigated, mainly because of the difficulty in collecting airway samples, such as sputum and bronchoalveolar lavage (BAL), routinely. Considering that only around 30% of people with COPD have productive cough (1), induce sputum production becomes the only viable alternative. Unfortunately, this is challenging to collect outside the hospital context and requires both specialized personnel and equipment. The acquisition of BAL samples is even more challenging, as it is limited to hospital centres and bronchoscopy in patients with COPD carries a significantly higher risk of complications such as pneumonia, respiratory failure and desaturation compared with those with normal lung function (9). In this scenario, saliva emerges as a viable non-invasive alternative to sampling the airway microbiota, which collection is simple and can be performed in different settings, namely at-home. Moreover, the oral and lower microbiotas are highly correlated (10), given the topological continuity between the niches, implying oral bacteria as the major colonizers of the lungs through aspiration (10–12).

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

An additional reason to choose saliva to evaluate the effect of PR in the airway microbiota, is the role of oral bacteria in nitrate metabolism. Exercise training, one of the main components of PR, stimulates the synthesis of nitric oxide by the human body, which is a key regulator of skeletal muscle blood flow, contractility, and mitochondrial function (13). Oral microbiota has been strongly implicated in exercise performance, mainly due to its essential role in nitratenitrite-nitric oxide pathway (14, 15), with recent studies showing nitrate oral supplementation to enhance PR effectiveness (16). The oral microbiota although acknowledged as essential for this positive effect, was never studied. On the other hand, microbiota modifications are frequently connected with an inflammatory response, which is well known to be modulated by exercise (17) and affected by PR, although with inconsistent results (18-20). Here, we have explored the association between PR and changes in oral microbiota and inflammatory markers of people with COPD to propose that PR effectiveness could be related, at least partially, with bacterial-driven immune regulation. Some of the results of this study have been previously reported in the form of abstracts (21-23).

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

Methods A prospective longitudinal cohort study was conducted. Ethical approvals were obtained from Administração Regional de Saúde Centro (64/2016), Centro Hospitalar do Baixo Vouga (including Estarreja's Hospital; 08-03-17) and Agrupamento dos Centros de Saúde do Baixo Vouga. Written informed consent was obtained from all participants. The study was reported following the "Strengthening the Reporting of Observational Studies in Epidemiology" statement (24). Participants were identified and referenced by clinicians who briefly explained the purposes of the study. Participants were eligible if diagnosed with COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria (25) and stable with no acute exacerbations in the month prior to enrolment. Exclusion criteria were presence of severe cardiac, musculoskeletal, or neuromuscular diseases, signs of cognitive impairment, active neoplasia or immune diseases, that could hinder their participation in PR. The opportunity to be integrated in the PR programme was offered to all participants. Those who did not accept to participate in the intervention but agreed with being monitored during the 5-month period were included in the control group. The intervention group (n=38) undertook a 12-week community-based PR program, whereas the control group (n=38) did not. Sociodemographic (age, sex), anthropometric (height and weight) and general clinical (smoking habits; medication, long-term oxygen use; number of acute exacerbations and hospitalizations in the past year and comorbidities - Charlson Comorbidity Index) data were collected with a structured questionnaire. Lung function was assessed with spirometry as recommended (26). Exercise capacity was assessed with the six-minute walk test (6MWT), a self-paced test of walking capacity (27). Impact of the disease was assessed with the COPD

assessment test (CAT), a 8-item questionnaire, each assessed with a 6-point Likert scale (28,

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

29). Dyspnoea at rest was assessed with the modified Borg Scale (mBorg), a 10-item scale. Clinical data and saliva samples were collected with a structured protocol adapted from the team published work (30). Response/non-response to PR was determined based on published minimal clinical importance differences (MCIDs), i.e., -1 point for mBorg (31); 25m for 6MWT (32) and -2 points for CAT (33). Deep sequencing of the V4 hypervariable region of 16S rRNA gene (F515/R806 primer pair) was performed for all samples. The bead assay LEGENDplex™ Human Inflammation Panel 1 (13-plex) (BioLegend, San Diego, CA, USA) was used to quantify inflammatory markers (IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-18, IL-23, and IL-33) in both groups in three timepoints, M0, M1 and M3. QIIME2 2020.8 (34, 35) was used to perform microbiota analyses. All statistical analyses were performed in GraphPad Prism 8 (36) and R software v 3.6.1 (37). Longitudinal models (Ime4 package (38)) and repeated-measures correlations (rmcorr package (39)) were performed in R software v 3.6.1 (37). The full description of the methodology used, including all steps of data collection, processing, and data analyses, are available in Supplementary file 1. Results Cohort characterisation Seventy-six individuals with COPD were included in this study, 38 (29 male, 72±9y, BMI: 26±4kg/m², FEV₁pp 49.2±16 % predicted, GOLD A-8, B-20, C-0, D-10) in the intervention group and the remaining 38 patients (31 male, 70±8y, BMI: 26.4±4.8kg/m², FEV₁pp 52.3±19.8 %

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

predicted, GOLD A-17, B-12, C-1, D-8) in the control group. Table 1 summarizes the baseline characteristics of the two groups. No significant differences were found between groups (see Table 1), and therefore, no adjustment for confounding factors was performed. Oral microbiota was similar between groups, being composed by two major phyla, Firmicutes (~43%) and Bacteroidetes (~24%), followed by Proteobacteria, Fusobacteria, Actinobacteria and ten low abundant phyla (<2%) (Supplementary figure 1). Changes in oral microbiota and inflammatory response are associated with PR We followed the temporal dynamics of beta-diversity (global rate of change (grc) of Weighted-Unifrac distance) in patients for a period of five months, including the 12 weeks of PR, to understand the impact of PR in microbiota composition. As a control for steady-state microbiota fluctuations, an independent cohort of patients who did not undergo PR, was surveyed for an equivalent amount of time. The dynamics of microbiota composition was significantly different between patients undergoing PR and controls (Figure 1A) (Imer on Weighted-Unifrac distance (grc), Group:Timepoint, F= 7.58, p<0.001). Principal coordinate analysis of pairwise distances (Weighted Unifrac) between groups in each timepoint showed significant differences in microbiota composition between groups upon one month of PR (Figure 1B) (PERMANOVA, F=2.3, p=0.038). The top four amplicon sequence variants (ASVs) responsible for individual's separation after the first month of PR were identified as Veillonella, Prevotella melaninogenica, Haemophilus parainfluenzae and Streptococcus.

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

Regarding microbiota diversity within individuals (alpha diversity), no significant changes were observed upon PR (Figure 1C) (Wilcoxon test on phylogenetic diversity: W= -85. p=0.48; Wilcoxon test on Shannon diversity: W= -1. p>0.99). Next, we compared the microbiota composition of the intervention group at baseline with that at M1, M2 and M3, to identify which taxa could have been affected by PR. PERMANOVA (MOvsM1: F=0.6, p_{adjust} >0.99; MOvsM2: F=1.3, p_{adjust} >0.99; MOvsM3: F=1.2, p_{adjust} >0.99; M0vsM4: F=1, p_{adjust} >0.99; M0vsM5: F=1.4, p_{adjust} =>0.99), ANCOM and LEfSe detected no significant differences between pre- and post-PR microbiota composition. This is compatible with the inherent correlation among the groups (composed by the same individuals) being stronger than differences introduced by PR. To overcome this limitation, given the longitudinal design of the experiment, we next tested for differences in taxa dynamics between the intervention and control group. This was performed using linear mixed-effect models. The temporal dynamics of the phylum Fusobacteria (Imer, Group:Time-point, F= 5.9, p=0.02) and several oral genera, such as Fusobacterium, Streptococcus, Dialister and Selenomonas were observed to be associated with PR (Table 2). Target testing for the top four ASVs distinguishing patients on M1 was also performed. Remarkably, significant alterations in the relative abundances of Prevotella melaninogenica and Streptococcus, two ASVs previously associated with disease severity in people with COPD (5), were also found (Imer, P. melaninogenica: Group:Time-point, F= 4.34, p=0.04; Imer, Streprococcus: Group:Time-point, F= 4.96, p=0.03). Considering that changes in microbiota are expected to be related with the inflammatory response, we further quantified a panel of 13 cytokines in three time points: M0, M1 and M3 in both intervention and control groups (Figure 2 and Supplementary figure 2). Significant

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

changes in the inflammatory profile of patients undergoing PR were observed (Figure 2). Specifically, upon one month of PR (M1) significant increases in the amounts of IL-10 and IL-18 were observed (Wilcoxon signed-rank: IL-10, W=163 p_{adjust}=0.038; IL-18, W=165 p_{adjust} =0.035). No significant changes were observed in the same period in control group. After three months of PR (M3), TNF- α , IL-1 β , IL-18, IL-10 and IL-6 were also significantly higher than at baseline (M0) (Wilcoxon signed-rank: IL-1 β , W=205 p_{adjust} =0.016; TNF- α , W=251 p_{adjust}=0.002; IL-10, W=263 p_{adjust}=0.0008; IL-6, W=189 p_{adjust}=0.03; IL-18, W=233 p_{adjust}=0.004). IL-10 and IL-6 also increased in the control group over the same time interval (Wilcoxon signed-rank: IL-10, W=225 p_{adjust} =0.018; IL-6, W=224 p_{adjust} =0.019), suggesting that these cytokines may be less stable. Regarding comparisons between the groups, shifts in IL-10 and IL-18 were significantly higher after 1 month of PR than the equivalent shifts in the control group (Mann-Whitney U-test, IL-10, U=180 p=0.043; IL-18, U=173 p=0.03). Over 3 months of PR, TNF- α , IL-18 and IL-10 had significantly higher shifts in the intervention than in the control group (Mann-Whitney U-test, TNF- α , U=246 p=0.04; IL-10, U=196 p=0.0004; IL-18, U=249 p=0.046). No additional significant differences were found in both groups (Supplementary figure 2). Interestingly, the variance associated with cytokine shifts over time was generally higher in the intervention than in the control group (Supplementary table 2). This is compatible with PR generally influencing cytokine levels. Oral microbiota and inflammatory response vary differentially among responders and nonresponders during PR PR improved all outcomes significantly (Wilcoxon test, p < 0.05), except for BMI (W=-114, p=0.31) and mBorg (W=37, p=0.5) (Supplementary table 3). Mean improvements only exceeded the MCID for exercise capacity (6MWT, mean-diff: 45.43; Cohen's d=0.34)

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

(Supplementary table 2). Supplementary figure 3 represents the overlap between responders (R) and non-responders (NR) to PR in exercise capacity (6MWT), impact of disease (CAT) and dyspnoea (mBorg). From 38 patients, 9 responded in dyspnoea (NR: n=29), 24 responded in exercise capacity (NR: n=14) and 24 responded in the impact of disease (NR: n=14). Six patients responded simultaneously to all three domains and six failed to respond to any domain. We analysed differences in microbiota composition among R and NR at M0 to query for a possible relationship between microbiota composition before PR and its effectiveness (Figure 3A). Principal coordinate analysis of pairwise distances (Weighted-Unifrac) showed significant differences between R and NR to dyspnoea (PERMANOVA p = 0.04) and captured 66% of total diversity (Figure 3B). Furthermore, the ASV responsible for the biggest separation between individuals in this analysis, was P. melaninogenica, whose frequency was below average in 75% of R. In accordance, the differential abundance analysis (LEfSe) showed that Prevotella (Figure 3C) was significantly enriched in NR to dyspnoea, with an effect-size of 9. No significant differences were observed for the other domains. Next, we used linear mixed effect models to compare the microbiota temporal dynamics between R and NR. Despite being differentially represented in R and NR (to dyspnoea) before PR, the frequency trajectory of *P. melaninogenica* was not significantly different among the two sets of patients during the intervention. Instead, several other taxa were found to have significantly different trajectories between the groups (Table 3 and Supplementary figure 4). Regarding the exercise capacity, the frequency trajectory of Lautropia (family Burkholderiaceae) was significantly different between R and NR (Imer, Group:Time-point, F= 2.9, p=0.02), reaching higher values in NR by the end of PR (Supplementary figure 3). The

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

dynamics of P. melaninogenica was distinct among R and NR (Imer, Group:Time-point, F= 2.6, p=0.03) to impact of disease (Supplementary figure 4). We compared the salivary levels of cytokines present in R and NR to question whether responsiveness to PR was related with the inflammatory response. Distinct patterns of inflammatory response were observed between R and NR, in all domains (Supplementary figure 5). Significant shifts during PR were always towards values higher than the baseline and occurred mainly in NR patients. Specifically, after PR, levels of TNFα, IL-1β, IL-18 and IL-10 were higher in NR of all domains, whereas only TNF- α and IL-10 showed significant changes in R patients (please see Supplementary figure 5 for details on the statistical tests results). Interestingly, the variance in cytokine shifts after PR was also mostly higher in NR than in R (Supplementary tables 4–6). PR effectiveness is related with specific bacteria-inflammation correlation signatures Independent analyses revealed an association between PR effectiveness and either changes in oral microbiota or inflammatory markers. We explored the patterns of longitudinal correlation between the two to understand in what extent PR effectiveness is linked with specific bacteria-inflammation associations. Figure 4 represents the network of significant correlations between inflammatory markers and bacterial genera inferred for the three domains. Remarkably, R and NR presented distinct patterns of bacteria-cytokine correlation (Figure 4). In all groups of NR, Lautropia showed a strong positive correlation with several proinflammatory cytokines, being the strongest with TNF- α in NR to exercise capacity (rmcorr = 0.65, p=0.002) and impact of the disease (rmcorr = 0.63, p=0.002). Conversely, Rothia presented a negative correlation with several pro-inflammatory markers in all groups of R,

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

with the strongest correlation with TNF- α (rmcorr = -0.73, p=0.007). Furthermore, Gemellaceae, was also negatively correlated with several inflammatory markers (strongest with IL-8, rmcorr = -0.69, p<0.0001) in R to exercise capacity and impact of the disease. Strikingly, except for a positive correlation between Haemophilus and IFN- $\alpha 2$ in R to impact of the disease (rmcorr = 0.43, p=0.03), all significant correlations with Proteobacteria were found in NR. We then performed a longitudinal correlation analysis between bacterial frequencies to gain further insight on bacterial interactions that might be related with PR responsiveness but are not necessarily linked with the immune response (Figure 5). In an effort to be conservative, since compositional data are intrinsically correlated, we chose a subset of taxa for this analysis. We included the major hubs found in the correlation between bacteria and inflammatory markers (Lautropia, Rothia, Gemellaceae and Kingella), plus five other oral taxa previously associated (5) with severity (Prevotella, P. melaninogenica, Streptococcus, Streptococcus sp., Haemophilus and Porphyromonas). In this analysis, Prevotella, whose frequency drops during PR in all NR (Supplementary figure 6 A-C), was negatively correlated with Haemophilus (rmcorr = -0.46, p=0.005), Streptococcus (rmcorr = -0.37, p=0.03) and Lautropia (rmcorr = -0.41, p=0.01) in NR to dyspnoea and with Haemophilus (rmcorr = -0.73, p=0.0004) in NR to exercise capacity. Conversely, during the first month of PR, the frequency of P. melaninogenica increased in all R (Supplementary figure 6A-C) and was negatively correlated with Kingella (R to dyspnoea, rmcorr = -0.59, p=0.04), Lautropia (R to exercise capacity, rmcorr = -0.52, p=0.004; R to impact of the disease, rmcorr = -0.43, p=0.03) and Streptococcus (R to impact of the disease, rmcorr = -0.41, p=0.04).

Gemellaceae and Rothia were strongly positively correlated in all R (strongest in dyspnoea, rmcorr = 0.9, p < 0.0001).

We show, for the first time, that oral microbiota changes with PR and that shifts in specific

Discussion

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

taxa appear to be strongly related with its effectiveness. By tracking two independent groups of patients for almost half a year we were able to discriminate between steady-state microbiota fluctuations and those possibly induced by PR. Contrary to the simple expectation that a well-established therapy should positively impact on patients' microbiota, a more complex reality was unravelled. Overall, PR was not able to boost microbiota diversity within patients, a hallmark of dysbiosis, causing only low magnitude changes in a few taxa, and elicited the secretion of several pro-inflammatory cytokines. However, when considering separately R and NR, taxa potentially related with responsiveness emerges and a differential inflammatory response becomes apparent. Previously, we have observed that low frequency of *Prevotella*, and in particular *P. melaninogenica*, was associated with a recent history of severe exacerbation (5). Here we observed that in the first month of PR Prevotella was boosted in R of all domains. We hypothesize that this boost could be directly or indirectly related with the ability to respond. For example, by directly inducing the reduction of lung epithelial cell permeability (by modulating expression of tight junction proteins) (40), or indirectly by promoting lung innate immune responses, particularly against Streptococcus pneumoniae (41) and Lautropia, to which it was negatively correlated.

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

In fact, it has been recently observed that P. melaninogenica is able to promote S. pneumoniae rapid clearance from the lung via TLR2 activation, recruitment of neutrophils and upregulation of TNF α and IL-10 (42). Interestingly, it was also observed that the aspiration of a mixture of 3 species of human oral commensals in mice, including P. melaninogenica, decreased host's susceptibility to S. pneumoniae (41). Supporting the hypothesis that, by counteracting Lautropia, Prevotella could be positively associated with PR effectiveness, is the observation that Lautropia is enriched in the oral microbiota of more severe cases of COPD (5) and co-occur with high levels of inflammatory markers in the eosinophilic COPD (43), an endotype that has been suggested to be predictive of worse outcome upon PR (44). Conversely, in NR to dyspnoea and exercise capacity, the opposite scenario was observed, that is, a clear decline in *Prevotella* upon PR, negatively correlated with *Haemophilus* (exercise capacity) and with Streptococcus and Lautropia (dyspnoea). A pro-inflammatory role in COPD has been repeatedly attributed to the first two taxa (45) which could likely contribute to the lack of response to this therapy. Besides this, Lautropia positively correlated with several proinflammatory markers in all groups of NR. Another striking observation, possibly related with the success of PR across the three domains, was the co-occurrence of Rothia and Gemellacea (in R) and its negative correlation with several pro-inflammatory markers during PR. Rothia mucilaginosa (the most abundant species of Rothia genus in our dataset) has been identified as an anti-inflammatory bacterium when present in the lungs (even in low abundance) of people with chronic respiratory diseases (46). This has been attributed to its ability to reduce the levels of several pro-inflammatory

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

cytokines and NF-kB activation in response to immune stimulation by pathogenic bacteria like Pseudomonas aeruginosa and Staphylococcus aureus (46). Considering the impact of PR on individual species, this was significant on the longitudinal dynamics of two particular ASVs, P. melaninogenica and Streptococcus, previously suggested to be associated with COPD severity (5). Moreover, the longitudinal dynamics of P. melaninogenica was distinct among R and NR to impact of the disease, supporting its importance to PR effectiveness. Besides its immunomodulatory properties, P. melaninogenica could have an additional role in PR effectiveness, since it belongs to the most prevalent genus of oral nitrate-reducing bacteria (47). These are essential for the nitrate nitric oxide pathway which is implicated in exercise performance and recovery (14, 15). Coherently, it has been shown that nitrate oral supplementation increased the beneficial effects of PR (16). Some limitations of our study need to be acknowledged. First, the use of saliva for COPD assessment is still exploratory. Although the microbiota of upper and lower airways is highly correlated, with oral bacteria being the major colonizers of the lungs through microaspiration (10-12), more studies, besides Melo-Dias et al (5) validating its biological relevance in the context of COPD are needed. Additionally, despite longitudinal studies including PR being very resource demanding, further works with similar design should be carried out, ideally including multicentric trials with larger cohorts to assess the robustness of the findings. Second, multiple confounders such as occurrence of exacerbations, treatment with inhaledcorticosteroids and/or antibiotics are present. Therefore, future studies should try to disentangle its effects from the PR-induced microbiota modulation.

Overall, besides responsiveness to PR being multidimensional and heterogeneous, giving rise to a moderate overlap in individuals response across domains, PR-induced changes in microbiota revealed surprisingly consistent patterns among R and NR. Furthermore, our findings suggest that PR effectiveness could be associated with a controlled inflammatory response to exercise, *i.e.*, the inflammatory response to exercise occurs accompanied by efficient regulatory mechanisms. These mechanisms can be mediated by bacteria and could be tested *in vitro*.

Future studies should address the implications and stability of these findings, clarifying the role of oral microbiota both as a biomarker of PR responsiveness and as a therapeutic target.

Acknowledgements:

Author contributions:

S. Melo-Dias and A. Sousa had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. A. Marques was responsible for ethical approval. A. Marques and A. Sousa were responsible for obtaining the funding, conceiving and designing the study. M. A. Mendes, J. Cravo and S. Souto-Miranda provided a substantial contribution for clinical data acquisition. S. Melo-Dias A. Furtado conducted sample processing, DNA extraction procedures and inflammatory markers quantification. S. Melo-Dias, M. Cabral, A. Furtado, C. R. Almeida and A. Sousa conducted bioinformatics and statistical analyses. S. Melo-Dias and A. Sousa drafted the manuscript. All authors critically revised the manuscript, ensured accuracy and integrity of the work and approved the final version to be published.

Funding:

This study is integrated in "PRIME – Pulmonary Rehabilitation and microbiota in exacerbations of COPD", "GENIAL – Genetic and Clinical markers of COPD trajectory", and "MicroAgeing - The role of microbiota in ageing", funded by Programa Operacional de Competitividade e Internacionalização - COMPETE, through Fundo Europeu de Desenvolvimento Regional - FEDER (POCI-010145-FEDER-028806 and POCI-01-0145-FEDER-007628), Fundação para a Ciência e Tecnologia - FCT (PTDC/DTP-PIC/2284/2014, PTDC/SAU-SER/28806/2017 and PTDC/BIA-EVL/30212/2017) and under the project UIDB/04501/2020. S. Melo-Dias was supported by Grant SFRH/BD/140908/2018 from FCT. A. Sousa was funded from national funds through FCT – Fundação para a Ciência e a Tecnologia, I.P., under the Scientific Employment Stimulus - Institutional Call - reference CEECINST/00026/2018.

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

Availability of data and materials: The dataset supporting the conclusions of this article is included within the article (and its additional file(s)). Furthermore, raw sequencing data was deposited in National Centre for Biotechnology Information's (NCBI) Sequence Read Archive (SRA) (BioProject PRJNA872131). Scripts for data analyses are provided in supplementary file 1. Ethics approval and consent to participate: A cross-sectional study was conducted. Ethical approvals were obtained from Administração Regional de Saúde Centro (64/2016) and from Centro Hospitalar do Baixo Vouga (08-03-17). Written informed consent was obtained from all participants. Consent for publication: Not applicable. Competing interests: S. Melo-Dias has nothing to disclose. M. Cabral has nothing to disclose. A. Furtado has nothing to disclose. S. Souto-Miranda has nothing to disclose. M. A. Mendes has nothing to disclose. J. Cravo has nothing to disclose. C. R. Almeida has nothing to disclose. A. Marques has nothing to disclose. A. Sousa has nothing to disclose. Acknowledgements: We are grateful to all people with COPD who accepted to participate in this study and to the team of Respiratory Research and Rehabilitation Laboratory, School of Health Sciences (Lab3R-ESSUA) for their support.

References

382

- 383 2022 GOLD Reports. Global Initiative for Chronic Obstructive Lung Disease - GOLD at
- https://goldcopd.org/2022-gold-reports-2/. 384
- 385 2. Casaburi R. Pulmonary Rehabilitation: Where We've Succeeded and Where We've Failed. COPD:
- Journal of Chronic Obstructive Pulmonary Disease 2018;15:219–222. 386
- 387 3. Augustin IML, Franssen FME, Houben-Wilke S, Janssen DJA, Gaffron S, Pennings H-J, Smeenk
- 388 FWJM, Pieters WR, Hoogerwerf A, Michels A-J, Merode F van, Wouters EFM, Spruit MA.
- 389 Multidimensional outcome assessment of pulmonary rehabilitation in traits-based clusters of
- 390 COPD patients. PLOS ONE 2022;17:e0263657.
- Spruit MA, Augustin IML, Vanfleteren LE, Janssen DJA, Gaffron S, Pennings H-J, Smeenk F, Pieters 391
- 392 W, van den Bergh JJAM, Michels A-J, Groenen MTJ, Rutten EPA, Wouters EFM, Franssen FME,
- 393 CIRO+ Rehabilitation Network. Differential response to pulmonary rehabilitation in COPD:
- 394 multidimensional profiling. Eur Respir J 2015;46:1625–1635.
- 395 Melo-Dias S, Valente C, Andrade L, Marques A, Sousa A. Saliva as a non-invasive specimen for
- COPD assessment. Respiratory Research 2022;23:16. 396
- 397 Budden KF, Shukla SD, Rehman SF, Bowerman KL, Keely S, Hugenholtz P, Armstrong-James DPH,
- 398 Adcock IM, Chotirmall SH, Chung KF, Hansbro PM. Functional effects of the microbiota in chronic
- 399 respiratory disease. The Lancet Respiratory Medicine 2019;7:907–920.
- 400 7. Marsland BJ, Gollwitzer ES. Host-microorganism interactions in lung diseases. Nat Rev Immunol
- 401 2014;14:827-835.
- Ubags NDJ, Marsland BJ. Mechanistic insight into the function of the microbiome in lung 402
- 403 diseases. European Respiratory Journal 2017;50:.
- 404 Rand IAD, Blaikley J, Booton R, Chaudhuri N, Gupta V, Khalid S, Mandal S, Martin J, Mills J, Navani
- 405 N, Rahman NM, Wrightson JM, Munavvar M, Group on behalf of the BTSBG. British Thoracic
- 406 Society guideline for diagnostic flexible bronchoscopy in adults: accredited by NICE. Thorax
- 407 2013;68:i1-i44.

- 10. Gaeckle NT, Pragman AA, Pendleton KM, Baldomero AK, Criner GJ. The Oral-Lung Axis: The 408 409 Impact of Oral Health on Lung Health. Respir Care 2020;65:1211–1220. 11. Mammen MJ, Scannapieco FA, Sethi S. Oral-lung microbiome interactions in lung diseases. 410 Periodontology 2000 2020;83:234-241. 411 412 12. Huffnagle GB, Dickson RP, Lukacs NW. The respiratory tract microbiome and lung inflammation: 413 a two-way street. Mucosal Immunol 2017;10:299-306. 414 13. Dyakova EY, Kapilevich LV, Shylko VG, Popov SV, Anfinogenova Y. Physical exercise associated 415 with NO production: signaling pathways and significance in health and disease. Front Cell Dev 416 Biol 2015;3:19. 14. Bescos R, Brookes ZLS, Belfield LA, Fernandez-Sanjurjo M, Casas-Agustench P. Modulation of oral 417 418 microbiota: A new frontier in exercise supplementation. PharmaNutrition 2020;14:100230. 419 15. Cutler C, Kiernan M, Willis JR, Gallardo-Alfaro L, Casas-Agustench P, White D, Hickson M, 420 Gabaldon T, Bescos R. Post-exercise hypotension and skeletal muscle oxygenation is regulated by 421 nitrate-reducing activity of oral bacteria. Free Radical Biology and Medicine 2019;143:252–259. 422 16. Pavitt MJ, Tanner RJ, Lewis A, Buttery S, Mehta B, Jefford H, Curtis KJ, Banya WAS, Husain S, 423 Satkunam K, Shrikrishna D, Man W, Polkey MI, Hopkinson NS. Oral nitrate supplementation to 424 enhance pulmonary rehabilitation in COPD: ON-EPIC a multicentre, double-blind, placebo-425 controlled, randomised parallel group study. *Thorax* 2020;75:547–555. 426 17. Clauss M, Gérard P, Mosca A, Leclerc M. Interplay Between Exercise and Gut Microbiome in the 427 Context of Human Health and Performance. Frontiers in Nutrition 2021;8:. 18. Gammal AIE, O'Farrell R, O'Mahony L, Shanahan F, Killian K, O'Connor TM. Systemic 428 429 Inflammatory Markers and Disease Severity in Chronic Obstructive Pulmonary Disease—The 430 Effect of Acute Exercise and Pulmonary Rehabilitation. Open Journal of Respiratory Diseases 431 2015;5:19-31.
- 19. van der Vlist J, Janssen TWJ. The potential anti-inflammatory effect of exercise in chronic 432 433 obstructive pulmonary disease. Respiration 2010;79:160-174.

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

20. Gigliotti F, Coli C, Lombardelli L, Romagnoli I, Logiodice F, Lanini B, Kullolli O, Binazzi B, Parronchi P, Maggi E, Piccinni M-P. Effect of pulmonary rehabilitation (PR) on inflammation status in patients with COPD. European Respiratory Journal 2015;46:. 21. Melo-Dias S, Cabral, Miguel, Furtado, Andreia, Souto-Miranda, Sara, Mendes, Maria Aurora, Cravo, João, Almeida, Catarina Rodrigues, Marques, Alda, Sousa, Ana A. The effect of pulmonary rehabilitation in salivary microbiota of people with chronic obstructive pulmonary disease: A longitudinal study. 2022; 22. Furtado, Andreia, Melo-Dias S, Cabral, Miguel, Marques A, Sousa A. The effect of pulmonary rehabilitation in salivary microbiota of people with chronic obstructive pulmonary disease: A longitudinal study. 2021; 23. Melo-Dias S, Cabral, Miguel, Furtado, Andreia, Souto-Miranda, Sara, Almeida, Catarina Rodrigues, Marques A, Sousa A. The Effectiveness of pulmonary rehabilitation in COPD is associated with specific shifts in oral microbiota. 2022; 24. Elm E von, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007;335:806-808. 25. GOLD - Global Strategy for Diagnosis, Management, and prevention of chronic obstructive pulmonary disease 2020 report. 2020. 1-141. 26. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement | American Journal of Respiratory and Critical Care Medicine. at https://www.atsjournals.org/doi/full/10.1164/rccm.201908-1590ST. 27. Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, McCormack MC, Carlin BW, Sciurba FC, Pitta F, Wanger J, MacIntyre N, Kaminsky DA, Culver BH, Revill SM, Hernandes NA, Andrianopoulos V, Camillo CA, Mitchell KE, Lee AL, Hill CJ, Singh SJ. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. European Respiratory Journal 2014;44:1428-1446.

- 460 28. Jones PW, Harding G, Berry P, Wiklund I, Chen W-H, Kline Leidy N. Development and first
- 461 validation of the COPD Assessment Test. European Respiratory Journal 2009;34:648-654.
- 29. Jones PW, Tabberer M, Chen W-H. Creating scenarios of the impact of COPD and their 462
- relationship to COPD Assessment Test (CAT™) scores. BMC Pulm Med 2011;11:42. 463
- 464 30. Marques A, Jácome C, Rebelo P, Paixão C, Oliveira A, Cruz J, Freitas C, Rua M, Loureiro H,
- 465 Peguinho C, Marques F, Simões A, Santos M, Martins P, André A, De Francesco S, Martins V,
- 466 Brooks D, Simão P. Improving access to community-based pulmonary rehabilitation: 3R protocol
- 467 for real-world settings with cost-benefit analysis. BMC Public Health 2019;19:676.
- 468 31. Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically
- important differences in pharmacological trials. Am J Respir Crit Care Med 2014;189:250–255. 469
- 32. Holland AE, Hill CJ, Rasekaba T, Lee A, Naughton MT, McDonald CF. Updating the minimal 470
- 471 important difference for six-minute walk distance in patients with chronic obstructive pulmonary
- 472 disease. Arch Phys Med Rehabil 2010;91:221-225.
- 473 33. Kon SSC, Canavan JL, Jones SE, Nolan CM, Clark AL, Dickson MJ, Haselden BM, Polkey MI, Man
- 474 WD-C. Minimum clinically important difference for the COPD Assessment Test: a prospective
- 475 analysis. Lancet Respir Med 2014;2:195-203.
- 34. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, Alexander H, Alm EJ, 476
- 477 Arumugam M, Asnicar F, Bai Y, Bisanz JE, Bittinger K, Brejnrod A, Brislawn CJ, Brown CT, Callahan
- 478 BJ, Caraballo-Rodríguez AM, Chase J, Cope EK, Da Silva R, Diener C, Dorrestein PC, Douglas GM,
- 479 Durall DM, Duvallet C, Edwardson CF, Ernst M, Estaki M, et al. Reproducible, interactive, scalable
- 480 and extensible microbiome data science using QIIME 2. Nat Biotechnol 2019;37:852-857.
- 481 35. QIIME 2. at https://giime2.org/>.
- 36. Prism GraphPad. at https://www.graphpad.com/scientific-software/prism/. 482
- 37. R: The R Project for Statistical Computing. at https://www.r-project.org/. 483
- 38. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using Ime4. Journal 484
- 485 of Statistical Software 2015;67:1-48.

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

Engl J Med 2019;381:1257-1266.

39. Bakdash JZ, Marusich LR. Repeated Measures Correlation. Frontiers in Psychology 2017;8:. 40. Ramsheh MY, Haldar K, Esteve-Codina A, Purser LF, Richardson M, Müller-Quernheim J, Greulich T, Nowinski A, Barta I, Stendardo M, Boschetto P, Korzybski D, Prasse A, Parr DG, Hohlfeld JM, Döme B, Welte T, Heath S, Gut I, Morrissey JA, Ziegler-Heitbrock L, Barer MR, Singh D, Brightling CE. Lung microbiome composition and bronchial epithelial gene expression in patients with COPD versus healthy individuals: a bacterial 16S rRNA gene sequencing and host transcriptomic analysis. The Lancet Microbe 2021;2:e300-e310. 41. Wu BG, Sulaiman I, Tsay J-CJ, Perez L, Franca B, Li Y, Wang J, Gonzalez AN, El-Ashmawy M, Carpenito J, Olsen E, Sauthoff M, Yie K, Liu X, Shen N, Clemente JC, Kapoor B, Zangari T, Mezzano V, Loomis C, Weiden MD, Koralov SB, D'Armiento J, Ahuja SK, Wu X-R, Weiser JN, Segal LN. Episodic Aspiration with Oral Commensals Induces a MyD88-dependent, Pulmonary T-Helper Cell Type 17 Response that Mitigates Susceptibility to Streptococcus pneumoniae. Am J Respir Crit Care Med 2021;203:1099-1111. 42. Horn KJ, Schopper MA, Drigot ZG, Clark SE. Airway Prevotella promote TLR2-dependent neutrophil activation and rapid clearance of Streptococcus pneumoniae from the lung. Nat Commun 2022;13:3321. 43. Wang Z, Locantore N, Haldar K, Ramsheh MY, Beech AS, Ma W, Brown JR, Tal-Singer R, Barer MR, Bafadhel M, Donaldson GC, Wedzicha JA, Singh D, Wilkinson TMA, Miller BE, Brightling CE. Inflammatory Endotype-associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal Analysis. Am J Respir Crit Care Med 2021;203:1488-1502. 44. Blood Eosinophils and Pulmonary Rehabilitation in COPD - PubMed. at https://pubmed.ncbi.nlm.nih.gov/34777651/>.

45. Celli BR, Wedzicha JA. Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease. N

46. Rothia mucilaginosa is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease | European Respiratory Society. at https://erj.ersjournals.com/content/early/2021/09/16/13993003.01293-2021.
47. Burleigh MC, Liddle L, Monaghan C, Muggeridge DJ, Sculthorpe N, Butcher JP, Henriquez FL, Allen JD, Easton C. Salivary nitrite production is elevated in individuals with a higher abundance of oral nitrate-reducing bacteria. *Free Radic Biol Med* 2018;120:80–88.

Figures

Veillonella,




Figure 1. Pulmonary rehabilitation modulates the microbiota composition of people with COPD, but does not affect alpha diversity. A) Global rate of change of beta diversity was estimated by subtraction of baseline values at all timepoints. Blue and grey loess lines were fitted over the data points representing beta-diversity relative to baseline along time in the intervention and control groups, respectively. The blue and grey areas represent the 0.95 confidence intervals. (M0=immediately prior PR; M1, M2, M3= 1,2,3 months after initiating PR; M4, M5=1 and 2 months after finishing PR). Intervention and control group presented different microbiota dynamics over the 5-month follow-up (LMER on Weighted Unifrac distance matrix, Group:Time-Point, p<0.001). The grey rectangle indicates the time interval spanning PR. **B)** Principal coordinate analysis of Weighted Unifrac distance between groups in each timepoint. (M0, M1, M2, M3, M4 and M5). Significant differences in microbiota composition between groups were observed in M1 (PERMANOVA, F=2.27, p=0.038). Blue and grey dots and ellipses represent intervention and control groups, respectively. The biplot represented in M1 show the top ASVs contributing for sample segregation (5608c3e6c9de9ceb79610e7786bd0ac4:

d0b698c7298bf04110a6d2f220879bfb:

melaninogenica,

Prevotella

e27680d4009f98f30248d823bc17fb8e:

Haemophilus

parainfluenzae,

a5189f77a2cfeab3bc1602ff5c8ac3e9: Streptococcus). **C)** No pre-post differences were observed in alpha diversity (Phylogenetic index and Shannon diversity index) in the Intervention group (Wilcoxon test: phylogenetic diversity: W= -85. p=0.48; Shannon diversity index: W=-1 p>0.99). *p<0.05, *p<0.01, ***p<0.001





Figure 2. The inflammatory profile of people with COPD changes upon pulmonary rehabilitation. Global rate of change represents the ratio between cytokine values measured at baseline and M1 or M3 (*i.e.* M1/M0 and M3/M0). Differences between M1 and the baseline and between M3 and the baseline were assessed by Wilcoxon signed-rank, in each group (intervention (blue) and control (grey)). Differences between groups at M1 and M3 were assessed by Mann-Whitney U-test. p<0.05, **p<0.01, **p<0.001. All cytokines for which a significant shift was observed are represented in this figure. Supplementary figure 2 shows the data for the remaining 8 cytokines.



549

550

551

552

553

554

555

556

557

558


559

560

561

562

Figure 3. Responders and non-responders present distinct microbiota profiles prior to pulmonary rehabilitation. A) Mean frequency of phyla and genera of bacteria present in Responders (R) and nonresponders (NR) to dyspnoea, exercise capacity and impact of the disease. B) R and NR to dyspnoea showed distinct microbiota composition prior to PR (PERMANOVA, p=0.04). PCoA analysis using Emperor on Weighted UniFrac distance. The biplot (grey arrows) represent the 3 most relevant ASVs for R and NR segregation. Prevotella melaninogenica (ASV: d0b698c7298bf04110a6d2f220879bfb) was the major contributor for segregation of R and NR followed by Veillonella dispar (ASV: 5608c3e6c9de9ceb79610e7786bd0ac) Haemophilus and parainfluenzae (ASV: e27680d4009f98f30248d823bc17fb8e). In blue is represented the area where samples presented a mean frequency of P. melaninogenica below the average of the dataset. 78% of R showed reduced mean frequencies of *P. melaninogenica* prior to PR while only 37% of NR followed the same trend. **C)** Cladogram highlighting differentially abundant genera between R and NR to dyspnoea prior to PR, inferred by linear discriminant analysis (LEfSe) at a significance cut-off of 3. Prevotella is significantly enriched in NR to dyspnoea, with an effect-size of 9.



proportional to the correlation coefficient.

Figure 4. Responders and non-responders to dyspnoea, exercise capacity and impact of the disease present distinct patterns of longitudinal bacteria-inflammatory markers' correlation. Correlation networks representing the repeated-measures correlations between bacteria and inflammatory markers in non-responders and responders to A) dyspnoea (rmcorr: [-0.75 – 0.52]) B) exercise capacity (rmcorr: [-0.73 – 0.66]) and C) impact of the disease (rmcorr: [-0.72 – 0.63]). Prior to the analysis, genera and ASVs: d0b698c7298bf04110a6d2f220879bfb and *a5189f77a2cfeab3bc1602ff5c8ac3e9* relative frequencies were transformed with arcsine square root transformation and inflammatory markers' concentration was transformed with log₁₀. The diameter of the nodes is proportional to the number of connections. Bacterial nodes are coloured with the colour code of each bacterial phyla (Firmicutes: yellow, Bacteroidetes: blue; Proteobacteria: red; Fusobacteria: green Actinobacteria: pink; Other phyla: grey). Inflammatory markers' nodes are represented in beige. Positive correlations are represented in red, while negative correlations are represented in blue. The width of edges is




Figure 5. Responders and non-responders to dyspnoea, exercise capacity and impact of the disease present distinct patterns of longitudinal bacteria-bacteria correlation. Correlation networks representing the longitudinal correlations between a subset of bacterial genera and ASVs: d0b698c7298bf04110a6d2f220879bfb and a5189f77a2cfeab3bc1602ff5c8ac3e9 non-responders and responders to A) dyspnoea (rmcorr: [-0.6 - 0.9]), B) exercise capacity (rmcorr: [-0.73 - 0.46]), and C)

579

580

581

582

584

585

586

587

588

589

590

591

592

593

594

595

impact of the disease (rmcorr: [-0.71 - 0.44]). Grey triangles highlight common patterns of bacterial correlations between domains. Empty blue and red circles represent cytokines with which the correspondent taxon negatively and positively correlates, respectively. These correlations were inferred through the correlation analysis between bacteria-inflammatory markers and are represented here to facilitate the interpretation of the bacteria-bacteria correlation network. Prior to the analysis, genera ASVs: d0b698c7298bf04110a6d2f220879bfb and a5189f77a2cfeab3bc1602ff5c8ac3e9 relative frequencies were transformed with arcsine square root transformation. The diameter of the nodes is proportional to the number of connections. Bacterial nodes were coloured according to the colour code of each bacterial phyla (Firmicutes: yellow, Bacteroidetes: blue; Proteobacteria: red; Fusobacteria: green Actinobacteria: pink; Other phyla: grey). Positive correlations were represented in red, while negative correlations were represented in blue. The width of edges is proportional to the correlation coefficient.

Tables

597

598

Table 1 – Sociodemographic, anthropometric, and clinical characteristics of individuals with chronic obstructive pulmonary disease at beginning of the study (n=76).

Characteristics	Intervention group (n=38)	Control group (n=38)	<i>p</i> -value
Age (years), mean±SD	72±9	70±7.60	0.19^{1}
Gender, n (%)			0.57^{2}
Male	29 (76%)	31 (82%)	
Female	9 (24%)	7 (18%)	
BMI (kg/m²), mean±SD	26±4	26.4±4.8	0.72^{3}
FEV _{1PP} , mean±SD	49.2±16.0	52.3±19.8	0.53^{1}
FVC _{PP} , mean±SD	77.8±17.3	76.9±27.9	0.68^{1}
Pack-years, mean±SD	42.4±43.0	53.0±51.2	0.27^{1}
Comorbidities (CCI), mean±SD	4.2±1.4	3.8±1.3	0.10^{1}
GOLD grade, n (%)			0.22^{4}
1	3 (8%)	6 (16%)	
2	14 (37%)	12 (32%)	
3	20 (53%)	15 (39%)	
4	1 (3%)	5 (13%)	
GOLD group, n (%)			0.069^{4}
Α	8 (21%)	17 (45%)	
В	20 (53%)	12 (32%)	
С	0 (0%)	1 (3%)	
D	10 (26%)	8 (21%)	
Medication, n (%)			
ICS	21 (55%)	19 (50%)	0.8^{4}
LABA	33 (87%)	30 (79%)	0.36^{4}
LAMA	24 (63%)	25 (66%)	>0.99
LTRA	2 (5%)	2 (5%)	>0.99 ⁴
SABA	9 (24%)	5 (13%)	0.37^{4}
SAMA	2 (5%)	0 (5%)	0.49^{4}
Macrolides in stability	0 (0%)	0 (0%)	>0.99
Number of exacerbations in the last year, n (%)			0.60^{2}
0 or 1	27 (71%)	29 (76%)	
≥2 or 1 with a hospitalisation	11 (29%)	9 (24%)	
Number of hospitalisations in the last year due to C	OPD, n (%)		0.67^{4}
0	32 (84%)	34 (89%)	
1	2 (5%)	3 (8%)	
2	3 (8%)	1 (3%)	
Missing values	1 (3%)	0 (0%)	
mBORG, mean±SD	0.8±1.3	0.5±1.0	0.3^{1}
CAT, mean±SD	17.1±8.1	11.7±7.4	0.003^{1}
Walked distance in 6MWT, mean±SD	389.0±133.9	457.5±82.8	0.045 ¹

SD: standard deviation, n (%): absolute and relative frequency, respectively; BMI: body mass index, FEV_{1pp}: forced expiratory volume in 1 second percent predicted, CCI: charlson comorbidity index, GOLD: global initiative for chronic obstructive lung disease, ICS: inhaled corticosteroids, LABA: longacting beta agonists, LAMA: long-acting muscarinic agonists, LTRA: leukotriene receptor antagonists, SABA: short-acting beta agonists, SAMA: short-acting muscarinic agonists, ¹ p-value obtained with Mann Whitney U-test, ² p-value obtained with Chi-square test, ³ p-value obtained with unpaired ttest with Welch's correction, ⁴ p-value obtained with Fisher's exact test.

599

600

601

602

603

604

605

Table 2 - Summary table of significant linear mixed effect models established to assess differences in microbiota dynamics between intervention and control groups.

OTUs/ASVs longitudinal dynamics	test's statistics	<i>p</i> -value (TP:Group)
Fusobacteria	5.86	0.016
Atopobium	5.51	0.019
Streptococcus	5.03	0.026
Dialister	6.39	0.012
Parvimonas	4.75	0.030
Fusobacterium	7.00	0.009
a5189f77a2cfeab3bc1602ff5c8ac3e9: Streptococcus	4.96	0.027
d0b698c7298bf04110a6d2f220879bfb: Prevotella melaninogenica	4.34	0.038
e27680d4009f98f30248d823bc17fb8e: Haemophilus parainfluenzae	0.18	0.673
5608c3e6c9de9ceb79610e7786bd0ac4: Veillonella	3.30	0.070

Models were produced based on the longitudinal relative frequencies of phyla, genera, and ASVs a5189f77a2cfeab3bc1602ff5c8ac3e9, d0b698c7298bf04110a6d2f220879bfb, e27680d4009f98f30248d823bc17fb8e and 5608c3e6c9de9ceb79610e7786bd0ac4. Data upon relative frequencies was transformed with arcsine and square root transformation. TP: time-point

Table 3 – Summary table of significant linear mixed effect models established to assess differences in microbiota dynamics between responders and non-responders to dyspnoea, exercise capacity and impact of the disease.

OTUs/ASVs longitudinal dynamics	test's	<i>p</i> -value		
	statistics	(TP:Group)		
Response to dyspnoea during exercise (Borg Modified Scale of Dyspnoea) MCID: -1 point				
Spirochaetes	2.33	0.046		
TM7	5.40	0.000		
Oribacterium	2.68	0.024		
Dialister	2.69	0.023		

Schwartzia	2.55	0.036
[Mogibacteriaceae]	2.45	0.036
Bulleidia	3.08	0.011
Treponema	2.33	0.046
Response to exercise capacity (6-minute walk test) MCID: +25m		
Lautropia	2.87	0.017
Response to impact of the disease (COPD assessment test) MCID: -2 point	ts	
d0b698c7298bf04110a6d2f220879bfb: Prevotella melaninogenica	2.58	0.029

Models were produced based on the longitudinal relative frequencies of phyla, genera, $a5189f77a2cfeab3bc1602ff5c8ac3e9 \quad \text{and} \quad d0b698c7298bf04110a6d2f220879bfb. \quad \text{Data} \quad \text{upon} \quad \text{relative}$ frequencies was transformed with arcsine and square root transformation. TP: time-point

606